Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach [0.03%]
Dame Idossa,Maeve A Hennessy,Alexis LeVee et al.
Dame Idossa et al.
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by lack of estrogen receptor expression, progesterone receptor expression, and human epidermal growth factor 2 overexpression/amplification. Given its...
Value, Access, and High-Quality Medical Oncology Care: Can We Have It All? [0.03%]
价值、可及性和高质量的医学肿瘤学护理：我们都能获得吗？
Ian F Tannock,Ajay Aggarwal,Haydee Verduzco-Aguirre et al.
Ian F Tannock et al.
Health systems, oncologists, and patients face a crisis in value of cancer care that has several components: interpretation of meaningful benefit, cost, and affordability that limits access to treatment and effective delivery of evidence-ba...
Tech That Scales: A Practical Framework for Artificial Intelligence-Enabled Cancer Care in Low- and Middle-Income Countries and Underserved US Counties [0.03%]
可扩展的技术：在中低收入国家和美国偏远地区启用人工智能的癌症治疗实用框架
Arturo Loaiza-Bonilla,Partha Basu,Eric Lucas et al.
Arturo Loaiza-Bonilla et al.
Cancer outcomes remain starkly unequal: 5-year survival rates for common malignancies in low- and middle-income countries (LMICs) often lag 20-40 percentage points behind high-income benchmarks, and similar disparities persist between well-...
Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics [0.03%]
colorectal cancer中新兴及成熟药物靶点：从生物学角度研发治疗手段
Rafael Grochot,Michela Bartolini,Sandra Algaze et al.
Rafael Grochot et al.
Alterations in the mitogen-activated protein kinase (MAPK) pathway play a central role in colorectal cancer (CRC) tumor biology, therapeutic response, and resistance. RAS oncogenic mutations are present in up to 35% of CRC; they represent c...
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer [0.03%]
三阴性乳腺癌二期和三期治愈疗法的个性化治疗
Alexis LeVee,Maeve A Hennessy,Dame Idossa et al.
Alexis LeVee et al.
The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease outcomes. Nevertheless, almost one in five pati...
Dyda Dao,Katarzyna Kozak,Anne Mailhot et al.
Dyda Dao et al.
Desmoid tumors (DTs) are rare fibroblastic neoplasms driven by altered Wnt signaling pathways, through activating mutations in β-catenin (CTNNB1) or loss of repressive APC. DTs are considered as intermediate neoplasms that can be locally a...
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape [0.03%]
三阴性乳腺癌的新兴疗法及治疗现状变迁
Maeve A Hennessy,Elizabeth Terman,Damé Idossa et al.
Maeve A Hennessy et al.
Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 overexpression. Historically, treatment options for TNBC have been limited, bec...
Less Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026 [0.03%]
减而不简，“同质化”不该是2026年肺癌治疗的发展策略
Martina Bortolot,Stephanie P L Saw,Erica Pietroluongo et al.
Martina Bortolot et al.
Although immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) have transformed the treatment of non-small cell lung cancer (NSCLC) across disease stages, real-world access remains highly unequal worldwide. Persistent cost barrie...
From Passion to Persistence: Nurturing Idealistic Roots to Extinguish Burnout [0.03%]
从激情到坚持：培育理想主义根基以消除职业耗竭
Sabe Sabesan,Wendy Oldenmenger,Mirjam Crul et al.
Sabe Sabesan et al.
Oncology clinicians often enter oncology with a strong sense of passion rooted in curiosity, service, and early formative experiences. Over time, however, this passion is tested by escalating clinical complexity, administrative burden, work...
Tailoring Management for Invasive Lobular Carcinoma: Imaging, Surgical Treatment, and Systemic Therapy Considerations [0.03%]
侵袭性小叶癌的诊治特点：影像学、手术及系统治疗考虑因素
Rita A Mukhtar,Matthew F Covington,Kristina Fanucci et al.
Rita A Mukhtar et al.
Invasive lobular carcinoma (ILC) represents the most common special subtype of breast cancer. Studies show challenges with imaging, surgical therapy, and systemic therapy selection, arguing for the need for improved treatment personalizatio...